Toward a COVID-19 Vaccine Strategy for Patients with Pemphigus on Rituximab

Overview

Journal J Am Acad Dermatol

Specialty Dermatology

Date 2020 Nov 1

PMID 33130180

Citations 8

Authors

Reid A Waldman

Marina Creed

Kelley Sharp

Jonas Adalsteinsson

Jaime Imitola

Timothy Durso

Jun Lu

Affiliations

Soon will be listed here.

Citing Articles

The challenges of the pandemic and the vaccination against covid-19 in pediatric patients with kidney disease.

Soeiro E, Penido M, Palma L, Bresolin N, Fonseca Lima E, Koch V J Bras Nefrol. 2022; 45(2):244-251.

PMID: 36282106 PMC: 10627141. DOI: 10.1590/2175-8239-JBN-2022-0081en.

A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.

Seirafianpour F, Pourriyahi H, Mesgarha M, Mohammad A, Shaka Z, Goodarzi A Dermatol Ther. 2022; 35(6):e15461.

PMID: 35316551 PMC: 9111423. DOI: 10.1111/dth.15461.

Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications.

Levit E, Longbrake E, Stoll S Mult Scler Relat Disord. 2022; 60:103719.

PMID: 35276450 PMC: 8890787. DOI: 10.1016/j.msard.2022.103719.

Impact of COVID-19 on autoimmune blistering diseases.

Drenovska K, Vassileva S, Tanev I, Joly P Clin Dermatol. 2021; 39(3):359-368.

PMID: 34517993 PMC: 7955939. DOI: 10.1016/j.clindermatol.2021.01.007.

Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).

Varley C, Winthrop K Curr Rheumatol Rep. 2021; 23(9):74.

PMID: 34269903 PMC: 8284038. DOI: 10.1007/s11926-021-01037-3.

References

Mohme S, Schmalzing M, Muller C, Vogt T, Goebeler M, Stoevesandt J . Immunizations in immunocompromised patients: a guide for dermatologists. J Dtsch Dermatol Ges. 2020; 18(7):699-723. DOI: 10.1111/ddg.14156. View

Pardi N, Hogan M, Porter F, Weissman D . mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4):261-279. PMC: 5906799. DOI: 10.1038/nrd.2017.243. View

Bar-Or A, Calkwood J, Chognot C, Evershed J, Fox E, Herman A . Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020; 95(14):e1999-e2008. PMC: 7843152. DOI: 10.1212/WNL.0000000000010380. View

Houot R, Levy R, Cartron G, Armand P . Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. Eur J Cancer. 2020; 136:4-6. PMC: 7315961. DOI: 10.1016/j.ejca.2020.06.017. View

Baker D, Roberts C, Pryce G, Kang A, Marta M, Reyes S . COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020; 202(2):149-161. PMC: 7405500. DOI: 10.1111/cei.13495. View